Dancing In Limbo: Living with Metastatic Breast Cancer

Three women share the uncertainty of living with metastatic breast cancer.


PUBLISHED: 1:00 AM, THU JUNE 12, 2008
Talk about this article with other patients, caregivers, and advocates in the Breast Cancer CURE discussion group.
Lilla Romeo invites her guests to gather around the dining room table of her elegant 11th floor New York City apartment where the lights of the city at night shine through two glass walls. As her guests settle in, Romeo, 61, points to a room monitor and says that, should they hear baby sounds, it’s her 2-year-old granddaughter asleep in a bedroom down the hall.

Lilla Romeo

Lilla Romeo, Ellen Hoffman, and Susan Langley have been living with metastatic breast cancer for eight, four, and one year, respectively.

Romeo, who was initially diagnosed at age 48 in 1995 while living in London, had a lumpectomy and radiation followed by five years of tamoxifen, a type of hormonal therapy. Her cancer returned in the same breast in 2000. Back in New York City by then, she had a mastectomy and began chemotherapy for the recurrence, now stage 3 breast cancer.

Three days before Romeo’s last chemotherapy session, a rash appeared on her mastectomy incision—a biopsy showed it was metastasis to the skin. With the cancer moving to another organ, Romeo’s cancer was stage 4. Further scans showed no other metastatic sites. A tiny spot on a lung was not thought to be cancer.

A lot had changed since her first diagnosis in 1995, so doctors tested her tumor and found it was positive for HER2, a gene present in normal breast cells that is overly abundant in some malignant cells, which meant a new biologically targeted drug called Herceptin (trastuzumab) could be used. Romeo’s initial tumor was estrogen receptor-positive (hormone-sensitive), but as sometimes happens, the stage 4 cancer was estrogen receptor-negative, a change that meant the tumor would not respond to hormonal treatment.

For five years, Romeo received Herceptin with the chemotherapy drug Navelbine (vinorelbine), both administered intravenously. With few side effects, she traveled to England, where she also holds citizenship, and Italy, where she was born. She received treatment at hospitals abroad and lived a full life, going to the gym, celebrating at children’s weddings, volunteering on a hotline for breast cancer patients, and becoming an activist for women with metastatic breast cancer. The treatment was working and the cancer on her chest was barely visible.

In 2005, Romeo says her oncologist felt her body needed a “chemo vacation,” so he took her off Navelbine (she continued taking Herceptin). For eight months, the rash remained stable; then it returned with what Romeo calls “a vengeance.” The Herceptin plus Navelbine combo worked again until February 2007, when the lung lesion, initially thought to be nothing, lit up on her scans, indicating the cancer had spread to her lung. Next, Romeo endured a nine-month roller coaster of drugs from the arsenal that has become available in the past 15 years.

Her oncologist tried three different drug combinations, and with each new cocktail, Romeo waited three months before scans showed if it was working. In the meantime, Romeo walked the all-too-familiar tightrope of waiting, watching, and hoping while the cancer grew and the list of possible drugs shrank.

On the night we gather Romeo has just learned that Abraxane (paclitaxel reformulation), the fourth option used by her oncologist, is working. Scans show dramatic improvement and nearly complete resolution in some areas. She has received a reprieve.

Talk about this article with other patients, caregivers, and advocates in the Breast Cancer CURE discussion group.
Special Feature
Share Your Art
Related Articles
Failure to Communicate: I Have Cancer But I'm OK
Am I alone in wanting to reassure everyone I meet?
New Therapy Shows Early Promise, Continues to Progress in Triple-Negative Breast Cancer
The designation, which will expedite the development and review of sacituzumab govitecan in TNBC, is based on a phase 2 trial in which the therapy induced a response rate of 31 percent in heavily pretreated patients with metastatic TNBC.
Flat and Fabulous: Life After Breast Cancer and a Double Mastectomy
Learning to accept my body after a double mastectomy.
Related Videos
Amanda L. Kong on Seeking a Second Opinion for Breast Cancer Care at a High Volume Hospital
Amanda L. Kong, discusses why patients should consider seeking a second opinion for their breast cancer diagnosis and care at a high volume hospital.
Amanda L. Kong on Breast Cancer Care at High Volume Hospitals
This study sought to identify patterns of breast cancer care at high volume hospitals.
Anees B. Chagpar on What to Expect After Contralateral Prophylactic Mastectomy
Anees B. Chagpar, director of the Breast Center at Smilow Cancer Hospital at Yale-New Haven, discusses what a patient can expect following a contralateral prophylactic mastectomy.